NSE:ZYDUSLIFE   ZYDUS LIFESCIENCES
received six observations from the US Food and Drug Administration following the regulator's inspection of the company’s active pharmaceutical ingredients facility in Changodar, India, from Dec. 14 to Dec. 22.

The company plans to address the observations within the stipulated tim

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.